Optimal Dose Finding Study ABT-199 and Ibrutinib in MCL
Status:
Active, not recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the optimal dosing scheme for the combination of
ibrutinib with ABT-199 for the treatment of relapsed or refractory mantle cell lymphoma
(MCL).